Star is continuing to provide on site maintenance support.

“Star is committed to carrying out the necessary inspections and taking corrective actions to support our customers and provide continuity throughout this challenging time.”

LONDON (PRWEB)
May 13, 2020

Star is advising customers that it is crucial to consider ongoing legislation relating to the safe operation of refrigeration and HVAC equipment. The Health & Safety Executive (HSE) recently stipulated the need for duty holders to remain compliant with regulations during the COVID-19 lockdown.

In line with government guidance, Star is carrying out vital service work for existing customers, to ensure continuity and compliance with refrigeration industry regulations. Star is also providing critical repair and maintenance services to essential industries during the COVID-19 pandemic.

Star Refrigeration Operations Director James Ward says: “We are continuing to undertake all essential maintenance work to ensure the smooth running of equipment and compliance with HSE regulations. Despite the current circumstances, it is important that plant operators continue to meet ongoing legal requirements.”

James Ward adds: “Star is committed to carrying out the necessary inspections and taking corrective actions to support our customers and provide continuity throughout this challenging time.”

Star’s nationwide refrigeration engineering team is continuing to operate in order to provide an essential support service for food production, processing, storage and distribution. Throughout the lockdown, Star has also provided critical repair and maintenance for cooling systems in key industries, including healthcare and IT/communication.

Star is UK’s largest refrigeration engineering company, with over 100 field engineering staff currently in operation across the UK during the COVID-19 pandemic. Star is working carefully within government guidelines to provide on site maintenance support, whilst ensuring the safety of staff, customers and the wider community.

Share article on social media or email:

Asymmetrex Presents the Benefits of Stem Cell Counting for Stem-Gene Clinical Trial Supply

If the FDA is starting to insist that that we have stem cell-specific dose for therapies, for clinical trials we are going to need it for supply as well.

BOSTON (PRWEB)
May 13, 2020

On May 12, the director of stem cell biotechnology company Asymmetrex continued to demonstrate the reach of his company’s tissue stem cell counting technology into all aspects of the stem cell regenerative medicine industry. Speaking online in Arena International’s Clinical Trial Supply 2020 conference, James Sherley, M.D., Ph.D. outlined how achieving a more effective supply chain for stem-gene therapy clinical trials will require the industry to advance to certification of the stem cell-specific properties of transported cell and gene therapies. Because of disruptions caused by the current global COVID19 crisis, this year’s annual conference was organized as a virtual experience online.

Asymmetrex’s AlphaSTEM Test™ technology is the first and only technology that can specifically quantity therapeutic tissue stem cells. The technology is applicable to therapies deploying either natural or genetically-engineered tissue stem cells. In his presentation, Sherley highlighted the prevalent misconception that therapeutic tissue stem cells can be counted by flow cytometry. Tissue stem cells cannot be counted by flow cytometry. Counting by flow cytometry requires biomarkers that specifically identify tissue stem cells. To date, despite years of attempts, such biomarkers have not been discovered.

In an earlier podcast series on “Counting Stem Cells” featured on the international stem cell industry networking platform RegMedNet, Sherley discussed the benefits of Asymmetrex’s technology to stem-gene therapy patients by providing essential dose information for their treatments. In his clinical trial supply presentation, he related the importance of the same care in ensuring that the potency and quality of stem cell treatments are preserved during transport for supply of stem-gene clinical trials.

Sherley also alerted his clinical trial supply audience to recent developments on the FDA regulatory landscape that are likely to impact future supply practices for stem-gene clinical trials. “If the FDA is starting to insist that that we have stem cell-specific dose for therapies, for clinical trials we are going to need it for supply as well.” Sherley based this prediction on a recent industry document developed by the FDA’s Standards Coordinating Body’s that identifies determination of unknown cell-specific doses as a needed standard for regenerative medicine.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the “AlphaSTEM Test™”) for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Share article on social media or email:

INC best places to work

“One thing we pride ourselves most on is our ability to preserve our corporate culture as we grow. Our team is our most valuable asset and we are truly like a family. Our evolution demonstrates what it takes to build a successful brand while still keeping a family-like culture.”

HUNTINGTON, N.Y. (PRWEB)
May 13, 2020

Compliancy Group is listed as one of Inc. Magazine’s Best Workplaces for 2020. Inc. analyzed data from more than 3,000 submissions, and chose 395 finalists for this year’s list. Compliancy Group’s employees took part in an employee survey, conducted by Quantum Workplace, on topics including trust, management effectiveness, perks, and confidence in the future. Inc. gathered, analyzed, and audited the data.

The strongest engagement scores came from companies that prioritize the most human elements of work. These Companies are leading the way in employee recognition, performance management, and diversity.

“One thing we pride ourselves most on is our ability to preserve our corporate culture as we grow. Our team is our most valuable asset and we are truly like a family. Our evolution demonstrates what it takes to build a successful brand while still keeping a family-like culture. Management is not only involved in employees’ professional success, but also invests in personal growth. This gives each employee the opportunity to grow within the company, love what they do, and express that through to our clients. Compliancy Group is an amazing place to work because it feels like home and I truly believe that everyone here feels the same way,” Marc Haskelson, CEO Compliancy Group.

“Building a great corporate culture comes only from strong leadership,” says Inc. magazine editor-in-chief Scott Omelianuk. “The companies on Inc.’s Best Workplaces list are setting an example that the whole country can learn from, especially now, when company culture is more important to the workforce than ever.

More from Compliancy Group:

Downloadable Content:

HIPAA News

Free HIPAA Compliance Checklist

Protected Health Information

What is a Business Associate

Compliance Software

About Compliancy Group:

HIPAA should be simple. That’s why Compliancy Group is the only HIPAA software with expert Compliance Coaches holding your hand to simplify compliance. Built by auditors, Compliancy Group gives you confidence in your compliance plan to reduce risk, increase patient loyalty, and profitability of your organization.

Why Compliancy Group?

HIPAA Audit Support, no client has ever failed an audit!

Total Solution

HIPAA Seal of Compliance

Dedicated Compliance Coaches

Visit https://www.compliancy-group.com or call 855.854.4722 to learn how simple compliance can be.

About Inc. Media:

The world’s most trusted business-media brand, Inc. offers entrepreneurs the knowledge, tools, connections, and community to build great companies. Its award-winning multi platform content reaches more than 50 million people each month across a variety of channels including websites, newsletters, social media, podcasts, and print. Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States. The global recognition that comes with inclusion in the 5000 gives the founders of the best businesses an opportunity to engage with an exclusive community of their peers, and the credibility that helps them drive sales and recruit talent. The associated Inc. 5000 Conference is part of a highly acclaimed portfolio of bespoke events produced byInc. For more information, visit http://www.inc.com.

About Quantum Workplace Quantum Workplace, based in Omaha, Nebraska, is an HR technology company that serves organizations through employee-engagement surveys, action-planning tools, exit surveys, peer-to-peer recognition, performance evaluations, goal tracking, and leadership assessment. For more information, visit QuantumWorkplace.com.

Share article on social media or email:

Drs. Desireé McCarthy-Keith, Anne Namnoum, Mark Perloe, and Pavna Brahma of Shady Grove Fertility Atlanta.

Patient, staff and community safety are of paramount importance, especially now. We’ve implemented new safety precautions at nearly every step of the patient experience. So while this is not business as usual, our commitment to help those struggling to conceive is strong and steadfast.

ATLANTA (PRWEB)
May 13, 2020

SGF, a pioneer in reproductive medicine, research, and innovation, and home to more than 85,000 babies born, announced today that SGF Atlanta has resumed all fertility procedures and treatments in its Atlanta, GA, location. While its Alpharetta, Buckhead-Piedmont, and Marietta offices remain closed temporarily, all Greater Atlanta area patients may start or resume full-service fertility care.

“Patient, staff and community safety are of paramount importance, especially now. We’ve implemented new safety precautions at nearly every step of the patient experience. So while this is not business as usual, our commitment to help those struggling to conceive is strong and steadfast,” said Pavna Brahma, M.D., of SGF’s Atlanta-Northside and Buckhead-Piedmont locations.

SGF Fertility Treatments Now Available in Georgia

Comprehensive fertility services, such as fertility and ovarian reserve testing and diagnosis, semen analysis, a full range of fertility treatments such as ovulation induction and intrauterine insemination (IUI), and cycle monitoring, in vitro fertilization (IVF), donor egg, sperm, and embryo treatment, genetic screening and testing, IVF for inherited genetic disease prevention, gestational carrier, egg freezing, fertility preservation for patients with cancer, and LGBTQ family building are all currently available at SGF Atlanta.

Patients seeking a fertility consult with an SGF physician may do so using during a secure, private video consult. “We have found the new video consults offer a uniquely intimate way of getting to know our patients during that first consult. For most, it’s a more comfortable and convenient experience being able to get questions answered and chart a plan for moving forward from comfort of their own home,” shared Anne Namnoum, M.D., of SGF’s Atlanta-Northside office.

“We are so inspired by the strength and endurance shown by our community during these uncertain times, and we recognize that while much of our world has been put on hold, our patients’ desire to have a baby remains. With improvements to safety and physical distancing protocols in place, we are overjoyed that our patients can again move forward with their family building goals at SGF,” said Mark Perloe, M.D., of SGF’s Atlanta-Northside office.

Read more about SGF’s safety protocols.

SGF Atlanta’s Physician Team Recognized as Top Docs

The SGF Atlanta team is recognized as Top Doctors for Infertility by Atlanta Magazine and operates under the leadership of Dr. Desireé McCarthy-Keith, SGF Atlanta’s Medical Director. SGF Atlanta brings significant advantages to patients. Recognized by Aetna’s Institutes of Excellence™ as well as being named a Center of Excellence by Optum,™ patients in Atlanta not only benefit from SGF’s extensive insurance participation but also exclusive financial programs that make accessing quality fertility care more affordable. (SGF Atlanta earned the distinction of Center of Excellence by demonstrating successful clinical outcomes and exceptional physician experience, staffing, and facilities, as well as maintaining accreditation status and continuous quality assurance.)

SGF Atlanta, home to Dr. McCarthy-Keith and fellow physicians, Drs. Anne Namnoum, Mark Perloe, and Pavna Brahma, has also earned numerous accolades in the region including Best Reproductive Endocrinology Practice by Kudzu—a distinction earned through a voting process by members of the surrounding Atlanta community.

SGF Atlanta is accepting new patients. Call 1-877-761-1967 or submit this brief form to schedule a virtual physician consult.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 85,000 babies born and counting. With 38 locations throughout FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, we offer patients virtual physician consults, individualized care, accept most insurance plans, and make treatment affordable through innovative financial options, including treatment guarantees. More physicians refer their patients to SGF than any other center. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

Share article on social media or email:

Xtalks Life Science Webinars

In this webinar, a workflow will be presented for the processing of 384 cell lysates with RNA-seq to generate expression data analyzed at the pathway level.

TORONTO (PRWEB)
May 13, 2020

Early stages of drug discovery often depend on relatively simple reporter assays or phenotypic readouts, providing little or no information on the drug’s mechanism of action (MOA). Gene expression profiling technologies like RNA sequencing (RNA-seq) enable a more comprehensive characterization of compounds by measuring the activity of molecular pathways. This information can complement phenotypic readouts and can be used to prioritize candidate compounds for further testing. RNA expression profiling also serves as a generic test that can be applied to any drug development pipeline without the need for target-dependent customization.

In this webinar, a workflow will be presented for the processing of 384 cell lysates with RNA-seq to generate expression data analyzed at the pathway level. The data show that shallow sequencing of crude cell lysates reproducibly detects over 5000 genes with at least ten reads. Subsampling of deep sequencing datasets demonstrated that differential pathway analysis is largely unaffected when reducing the number of genes to this level. Consequently, reliable pathway insights can be obtained at high throughput and relatively low cost while not being limited to a predefined set of genes or pathways.

In cell perturbation screenings (small molecules, RNAi, antisense or CRISPR), the application can provide in-depth information on the mode of action underlying the induced cellular phenotypes as well as molecular similarity scores to identify those perturbations acting similar to a reference condition or via shared molecular mechanisms. This methodology can also be applied to repurpose off-target siRNA hits from library screens to reveal novel candidate therapeutic targets for drug development.

Join Pieter Mestdagh PhD, Senior Scientist, Biogazelle in a live webinar on Wednesday, May 27, 2020 at 9am EDT (2pm BST/UK).

For more information or to register for this event, visit Applications of High Throughput Gene Expression Profiling in Early Drug Discovery.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

RPM and telehealth was still trying to persuade buyers of the usefulness, the business case when COVID-19 hit. Those conversations have been made easier, and we’ve even heard that POs that were pending hospital approval have been rushed through.

ARLINGTON, Va. (PRWEB)
May 13, 2020

COVID-19 has forced the separation of healthcare providers from patients in many cases, making the case for remote patient monitoring and telehealth systems. The global patient monitoring and telehealth market is estimated to be worth about $42 billion in 2019, inclusive of devices, peripherals, software, packaged services, monitoring services and other applications, according to a report from Kalorama Information, part of Science and Medicine Group, a market research firm.

“RPM and telehealth was still trying to persuade buyers of the usefulness, the business case when COVID-19 hit,” said Bruce Carlson, Publisher of Kalorama Information. “Those conversations have been made easier, and we’ve even heard that POs that were pending hospital approval have been rushed through.”

Temporarily, restraints due to HIPPA legislation have been lifted. The Office for Civil Rights (OCR) at the Department of Health and Human Services (HHS) is responsible for enforcing certain regulations issued under the Health Insurance Portability and Accountability Act of 1996 (HIPAA) indicated that “A covered health care provider that wants to use audio or video communication technology to provide telehealth to patients during the COVID-19 nationwide public health emergency can use any non-public facing remote communication product that is available to communicate with patients.”

No longer is telehealth for rural patients alone. Legislation from the House details that for qualified providers, an emergency waiver will allow telehealth to be reimbursed by Medicare.

The interest in telemedicine and telehealth has exploded over the last decade. Involvement in this care segment has several benefits and hospitals, caregivers, device manufacturers, and patients are continuing to jump on board with acceptance using this technology. There are more than 700 clinical trials using telehealth recently completed, currently underway. The global patient monitoring and telehealth market has continued its expansion in both the institutional and home segments of the health market with the United States and many European countries at the forefront of implementation.

Among the trends Kalorama analysts have noticed recently include the following:

• – Increasing demand and business opportunities as a result of COVID-19.
• – Pending POs for telehealth equipment and services that hospitals were delaying being completed as a response to COVID.
• – Companies are facing growing difficulties in accessing supplies to provide monitoring equipment.
• – Companies are experiencing longer lead times for manufacturing monitoring equipment.
• – Companies have had to expand capacity for surges in use; one company reported a move to a hosting platform that could handle the increased volume – a move that has not come without several hurdles to implement.
• – Most companies report increased and enhanced security software upgrades.
• – Still uncertainty if widespread telehealth reimbursement and other implemented programs will sustain post-COVID.
• – Inquiries, New Orders are up

Kalorama Information’s Remote Patient Monitoring report details the companies in the market and the size of the market by application. It can be found at: https://kaloramainformation.com/product/remote-patient-monitoring-and-telehealth-market/

About Kalorama Information

For more than 30 years, Kalorama Information has been a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, healthcare, medical devices, and pharmaceuticals.

Share article on social media or email:

This FDA clearance is the culmination of years of work reshaping the scale of our core product and completely alters the trajectory of Critical Alert

JACKSONVILLE, Fla. (PRWEB)
May 13, 2020

Critical Alert, a leading provider of enterprise-class patient communications software for hospitals and healthcare systems, announced today it has been granted FDA clearance for its CommonPath Enterprise software platform as a Class II Medical Device. The platform provides the intelligent routing of patient events and medical device alarms with robust analytics on a single enterprise platform.

CommonPath Enterprise, architected to be centrally configured and managed from a single data center, can be deployed across any size healthcare enterprise. The SaaS platform includes support for UL-1069 nurse call with the native ability to use any third-party call light hardware, medical devices, and clinical communication & collaboration platforms.

“This clearance is the culmination of years of work reshaping the scale of our core product and completely alters the trajectory of Critical Alert,” said April Hjort, vice president of research and development at the company. “Our current and future customers will benefit from this commitment to innovation and interoperability. I am proud to have been part of this transformation and excited to see the adoption of our innovative approach in the marketplace,” continued Hjort.

CommonPath Enterprise transforms a disparate patient communication ecosystem into a connected, real-time health system enabling caregivers to provide more efficient and informed responses to patient needs and safety. It also empowers leadership with intuitive easy-to-configure workflow and analytics software for continuous improvement of processes.

“CommonPath Enterprise is unique in the nurse call industry in that, as a software-based platform, it can function on our signaling equipment, as well as that made by third-party manufacturers, breathing new life into legacy systems without turning a system upgrade into a construction project,” stated John Elms, CEO at Critical Alert. “With FDA clearance, we can now bring convergence to physical requests from the patients with physiological needs communicated by connected medical devices on the same modern and cybersecure platform,” continued Elms.

About Critical Alert

Critical Alert offers a cost-effective solution set of enterprise-class, software-based products, services and strategies that enable hospitals and healthcare enterprises to give patients a voice, empower clinical staff with actionable intelligence, and unburden their support and IT teams. CommonPath Enterprise, our software-driven patient communications platform, is FDA-cleared as a Class II Medical Device and includes UL-1069 nurse call, overlay software to modernize legacy nurse call systems, alarm management & event notification, patient experience monitoring, advanced clinical analytics, and a portfolio of integrated partner offerings.

For more information, visit: http://criticalalert.com/alarm-management/ and follow on LinkedIn.

Critical Alert is a trademark of Critical Alert. All other product or service names are the property of their respective owners.

Share article on social media or email:

Future Lab: Optimizing Workflows in the Life Science Lab

Finding the right lab equipment can be really challenging and I see Future Lab as an amazing opportunity to simplify this journey by providing our expertise on the lab tools and technologies in a way that the scientist can immediately adopt to their work.

SAN FRANCISCO (PRWEB)
May 13, 2020

In collaboration with Sartorius, Biocompare has introduced a new content hub called Future Lab: Optimizing Workflows in the Life Science Lab. The comprehensive information source was created for life scientists to help them optimize workflows in their lab, from water purification and liquid handling to contamination control.

The content hub features the latest guidance about enabling tools and technologies, the best ways to streamline workflows, and practical tips from experts. With Sartorius as its sponsor, Optimizing Workflows in the Life Science Lab will deliver the essential information scientists need to improve laboratory operations so they can spend more time on their research.

Future Lab is an interactive information resource designed to showcase the latest breakthroughs, trends, news, and products within specific scientific niches. Since their launch four years ago, Future Lab content hubs have become invaluable resources for life scientists around the world. The hubs are updated weekly, and regular alerts drive engagement with registered users.

“We are really excited to have developed this platform to allow the more than 3.3 million scientists who visit Biocompare each year to consume content in a much more engaging environment. This fully supports Biocompare’s mission to educate scientists in the latest technology while providing the tool provider community a unique and novel way to engage with our audience,” says Joan Boyce, VP & GM of Biocompare.

Previous Future Labs have focused on other integral topics in life science research including Next-Gen Sequencing, Functional Genomic Screening, Automated Sample Prep, Antibody Therapeutics, Genetic Analysis, Live Cell Imaging, Protein Production, Immunodetection, Cell Culture, Liquid Handling, Flow Cytometry, and Biopharmaceutical Analysis.

“Researchers should have a chance to focus their time and efforts on science. Finding the right lab equipment can be really challenging and I see Future Lab as an amazing opportunity to simplify this journey by providing our expertise on the lab tools and technologies in a way that the scientist can immediately adopt to their work,” added Emilia Varhimo, Head of Product Management, Pipetting & Dispensing at Sartorius.

About Biocompare

Biocompare, a Division of CompareNetworks, Inc., is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative resource that enables them to make better products, technology, and service purchasing decisions. Produced by scientists, Biocompare’s mission is to provide free, time-saving services to life science researchers, allowing scientists to find and learn about the technologies that drive discovery. Biocompare continually strives to serve the life science community by providing new and improved online services that facilitate product discovery and technology education. For more information, please visit http://www.biocompare.com.

Share article on social media or email:

“This designation recognizes Dr. Ali Sarram as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
May 13, 2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Ali Sarram M.D., Colorado Urology in Parker, CO, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Sarram has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“This designation recognizes Dr. Ali Sarram as a UroLift Center of Excellence for his commitment to providing safe and effective treatment to patients with BPH,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “We are pleased to see the continued acceptance of the UroLift System as a standard of care treatment that may allow men to discontinue the use of BPH medications and improve their quality of life.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

# # #

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email: